Displaying drugs 8976 - 9000 of 11105 in total
Garetosmab
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Tidutamab
Tidutamab is under investigation in clinical trial NCT04590781 (Safety and Efficacy of Xmab18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer).
Investigational
Lirentelimab
Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Investigational
(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol
Experimental
Matched Name: … (R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol …
Matched Iupac: … (R)-(pyridin-4-yl)({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl})methanol …
Matched Iupac: … (R)-(pyridin-4-yl)({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl})methanol …
L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide
Experimental
Matched Iupac: … (2S)-2-[(2S)-2-aminopropanamido]-N-[(2S,3R)-3-hydroxy-1-phenylbutan-2-yl]propanamide …
Cystic fibrosis transmembrane conductance regulator
Cystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis).
Investigational
Ertumaxomab
Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
Investigational
5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine
Experimental
Matched Name: … 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine …
Matched Iupac: … 5-(4-methoxyphenoxy)quinazoline-2,4-diamine …
Matched Iupac: … 5-(4-methoxyphenoxy)quinazoline-2,4-diamine …
Pyridoxyl-Glutamic Acid-5'-Monophosphate
Experimental
Matched Name: … Pyridoxyl-Glutamic Acid-5'-Monophosphate …
Matched Iupac: … 4-({[(1S)-1,3-dicarboxypropyl]amino}methyl)-3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-1-ium …
Matched Iupac: … 4-({[(1S)-1,3-dicarboxypropyl]amino}methyl)-3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-1-ium …
Bis(5-Amidino-2-Benzimidazolyl)Methanone
Experimental
Matched Name: … Bis(5-Amidino-2-Benzimidazolyl)Methanone …
Matched Iupac: … 2-(6-carbamimidoyl-1H-1,3-benzodiazole-2-carbonyl)-1H-1,3-benzodiazole-5-carboximidamide …
Matched Iupac: … 2-(6-carbamimidoyl-1H-1,3-benzodiazole-2-carbonyl)-1H-1,3-benzodiazole-5-carboximidamide …
Temafloxacin
Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Withdrawn
Matched Iupac: … 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Fleroxacin
Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
Experimental
Matched Iupac: … 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Difloxacin
Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration. However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.
Vet approved
Matched Iupac: … 6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Matched Salts cas: … 91296-86-5 …
Matched Salts cas: … 91296-86-5 …
Pradofloxacin
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Vet approved
Matched Iupac: … -octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3- …
2-Amino-4h-1,3-Benzoxathiin-4-Ol
Experimental
3,6,9,12,15-PENTAOXATRICOSAN-1-OL
Experimental
(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid
(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid is a solid. This compound belongs to the benzenes and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This medication targets the protein beta-lactamase.
Experimental
Matched Iupac: … [(R)-phenyl[2-(thiophen-2-yl)acetamido]methyl]boronic acid …
Capsicum annuum whole
Capsicum annuum whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
3,6,9,12,15-Pentaoxaheptadecane
Experimental
SARS-CoV-2 Sclamp
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … The SARS-CoV-2 Sclamp Vaccine was developed within 3 weeks and moved immediately into preclinical testing …
Prizloncabtagene autoleucel
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Investigational
Liothyronine I-131
Liothyronine I-131 has been used in trials studying the treatment of Tricuspid Atresia and Heart Defects, Congenital.
Investigational
Matched Iupac: … (2S)-2-amino-3-{4-[4-hydroxy-3-(¹³¹I)iodophenoxy]-3,5-di(¹³¹I)iodophenyl}propanoic acid …
Displaying drugs 8976 - 9000 of 11105 in total